만성골수성백혈병 진단용 다중(multiplex)RT-PCR용 프라이머, 이 프라이머를 포함하는 진단조성물 및 키트
    1.
    发明公开
    만성골수성백혈병 진단용 다중(multiplex)RT-PCR용 프라이머, 이 프라이머를 포함하는 진단조성물 및 키트 有权
    多重RT-PCR引物,一种组合物和一个包含用于诊断慢性MYELOID LEUKEMIA的试剂盒

    公开(公告)号:KR1020080010597A

    公开(公告)日:2008-01-31

    申请号:KR1020060070818

    申请日:2006-07-27

    CPC classification number: C12Q1/6858 C12Q1/686 C12Q2521/107 C12Q2537/143

    Abstract: Multiplex RT-PCR(reverse transcription-polymerase chain reaction) primers are provided to screen BCR(breakpoint cluster region)-ABL fusion genes required for diagnosis of chronic myeloid leukemia, detect breakpoints and transcript frequency of various types of BCR-ABL genes without cell genetic analysis and reduce detection time. Oligonucleotide primers for amplifying BCR-ABL fusion genes comprise the nucleotide sequence of SEQ ID NO:1 and SEQ ID NO:9 for sense primer, and SEQ ID NO:2 for antisense primer. A composition for amplifying BCR-ABL fusion genes comprises the oligonucleotide primers of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:9, and a multiplex RT-PCR amplification mixture containing reaction buffer, deoxynucleotide, Taq-polymerase and reverse transcriptase. A diagnostic kit of BCR-ABL fusion genes comprises the composition for amplifying BCR-ABL fusion genes and cDNA of standard BCR-ABL fusion protein. A method for amplifying BCR-ABL fusion genes comprises the steps of: (1) obtaining mRNA(messenger RNA) from a biological sample; and (2) performing multiplex RT-PCR of the mRNA by using the oligonucleotide primers of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:9.

    Abstract translation: 提供多重RT-PCR(逆转录 - 聚合酶链式反应)引物,筛选诊断慢性粒细胞白血病所需的BCR(断点簇区)-ABL融合基因,检测各种BCR-ABL基因无细胞的断裂点和转录本频率 遗传分析,缩短检测时间。 用于扩增BCR-ABL融合基因的寡核苷酸引物包含用于正义引物的SEQ ID NO:1和SEQ ID NO:9的核苷酸序列,反义引物的SEQ ID NO:2。 用于扩增BCR-ABL融合基因的组合物包含SEQ ID NO:1,SEQ ID NO:2和SEQ ID NO:9的寡核苷酸引物,以及含有反应缓冲液,脱氧核苷酸,Taq聚合酶和 逆转录酶。 BCR-ABL融合基因的诊断试剂盒包括用于扩增BCR-ABL融合基因的组合物和标准BCR-ABL融合蛋白的cDNA。 扩增BCR-ABL融合基因的方法包括以下步骤:(1)从生物样品获得mRNA(信使RNA); 和(2)通过使用SEQ ID NO:1,SEQ ID NO:2和SEQ ID NO:9的寡核苷酸引物进行mRNA的多重RT-PCR。

Patent Agency Ranking